1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Rapid Micro Biosystems reported first quarter 2026 total revenue of $8.0 million, up 11.1% from a year earlier, with product revenue up 36.0%. The net loss widened to $14.3 million from $11.3 million, and the company reaffirmed its full year 2026 total revenue guidance of $37.0 million to $41.0 million. For shareholders, revenue growth is offset by a larger loss and cash, short-term investments and restricted cash of about $23 million as of March 31, 2026.
Total revenue rose 11.1% to $8.0 million; product revenue rose 36.0% to $5.6 million, while service revenue fell 21.9% to $2.4 million.
Net loss was $14.3 million, or $0.31 per share, versus $11.3 million, or $0.26 per share, in the first quarter of 2025.
Full year 2026 total revenue guidance of $37.0 million to $41.0 million was reaffirmed, along with a gross margin target of approximately 20%.
Cash, short-term investments and restricted cash were about $23 million on March 31, 2026, down from $38.6 million on December 31, 2025.
Nortech Systems reported first quarter 2026 results, with net sales up 12.7% to $30.3 million and a net loss of $34 thousand, or $(0.01) per share, compared with a $1.3 million loss, or $(0.48) per share, a year earlier. Revenue growth and a much smaller loss improve the picture for shareholders, while the company also closed $17.2 million in debt financing and reported a total backlog of $90.8 million.
Net sales were $30.3 million in Q1 2026, up from $26.9 million in Q1 2025.
Net loss narrowed to $34 thousand, or $(0.01) per basic share, from $1.3 million, or $(0.48) per share.
Adjusted EBITDA was $350 thousand, compared with a $(1.0) million loss in Q1 2025.
90-day backlog was $31.5 million as of March 31, 2026, up from $26.7 million a year earlier.
Investcorp Credit Management BDC reported a net decrease in net assets from operations of $8.6 million, or $0.60 per share, for the quarter ended March 31, 2026, compared with a net increase of $2.2 million, or $0.15 per share, a year earlier. Net asset value per share fell to $3.65 from $4.25 at December 31, 2025, and no distribution was paid, versus $0.12 per share in the prior-year quarter.
Net decrease in net assets from operations was $8.6 million ($0.60 per share), versus a net increase of $2.2 million ($0.15 per share) in the same quarter of 2025.
Net asset value per share fell $0.60 to $3.65; total net assets were $52.7 million, down from $61.3 million at December 31, 2025.
Net investment income before taxes was $0.3 million ($0.02 per share), compared with $0.7 million a year earlier; distributions paid were $0.00 per share.
On March 30, 2026, the company refinanced its 4.875% Notes with new unsecured notes from an affiliate of its investment adviser, bearing SOFR plus 5.5% and maturing July 1, 2029; the Capital One revolving facility was cut from $100 million
Marchex reported first-quarter 2026 revenue of $10.6 million, down from $11.4 million a year earlier, while its net loss narrowed to $1.7 million from $2.0 million. The company raised its second-quarter 2026 Adjusted EBITDA guidance to $1.6 million to $1.8 million, up from prior guidance of more than $1 million, and said the proposed Archenia acquisition is expected to close in July 2026 if stockholders approve it.
Q1 2026 revenue was $10.6 million versus $11.4 million in Q1 2025.
Net loss was $1.7 million, or $(0.04) per diluted share, versus $2.0 million, or $(0.05), a year earlier.
Q2 2026 Adjusted EBITDA is now expected to be $1.6 million to $1.8 million, up from prior guidance of more than $1 million.
Marchex signed a Stock Purchase Agreement on May 8, 2026 to acquire 100% of Archenia, Inc.; closing is expected in July 2026, subject to majority approval by disinterested stockholders.
Armlogi reported results for the quarter and first nine months ended March 31, 2026. Third-quarter revenue fell 9.1% to $41.7 million and the quarterly net loss widened to $5.1 million from $3.8 million, while nine-month revenue rose 2.3% to $142.7 million and the nine-month net loss grew to $15.4 million from $10.1 million. The filing shows weaker profitability and lower cash for shareholders, with the company attributing the quarterly gross loss partly to temporary labor costs from an inventory reorganization at its California warehouses.
Q3 revenue of $41.7 million, down 9.1% from $45.8 million; transportation services revenue fell 19.1% to $23.1 million.
Q3 gross loss of $1.9 million (gross margin of -4.5%) versus a gross profit of $0.3 million a year earlier; temporary labor costs of approximately $1.3 million tied to the California inventory reorganization.
Nine-month revenue rose 2.3% to $142.7 million, with warehousing services revenue up 19.9% to $55.5 million.
Cash and restricted cash totaled $7.1 million as of March 31, 2026, compared with $13.6 million as of June 30, 2025.
Energous reported first quarter 2026 revenue of approximately $3.1 million, up from $0.3 million a year earlier and 1% above the fourth quarter of 2025, marking its fifth consecutive quarter of revenue growth. The net loss narrowed to $1.7 million, or $0.43 per share, from $3.4 million, or $3.55 per share, a year earlier, and cash and equivalents stood at $36.6 million at March 31, 2026.
Revenue of approximately $3.1 million for the quarter ended March 31, 2026, versus $0.3 million in the same period of 2025
Gross margin of 36%, with gross profit of $1.1 million
GAAP net loss of approximately $1.7 million ($0.43 per share) versus $3.4 million ($3.55 per share) a year earlier
During the quarter the company raised $31.9 million net under its at-the-market program and has not sold shares under it since March 19, 2026
Eledon Pharmaceuticals reported a first quarter 2026 net loss of $39.0 million, or $0.33 per share, up from $6.5 million, or $0.08 per share, a year earlier. The loss was driven mainly by a $19.0 million non-cash charge from changes in the fair value of warrant liabilities, and cash, cash equivalents and short-term investments fell to $111.1 million, which the company says will fund operations into 2Q 2027.
Net loss was $39.0 million for the quarter ended March 31, 2026, versus $6.5 million a year earlier, including a $19.0 million non-cash warrant fair value loss compared with a $10.1 million gain in 2025.
Excluding warrant fair value changes, the net loss was $20.1 million, compared with $16.6 million in the first quarter of 2025.
Research and development expenses rose to $17.2 million from $13.5 million, while general and administrative expenses fell to $4.0 million from $4.4 million.
Cash and short-term investments totaled $111.1 million at March 31, 2026, down from $133.3 million at December 31, 2025.
Hawkins reported fiscal 2026 sales of $1.08 billion, up 11%, but diluted earnings per share fell 3% to $3.91 and net income fell to $81.5 million from $84.3 million. The company attributed the profit decline mainly to about $16.5 million in higher amortization, interest expense and earnout-related fair value accretion from six acquisitions, and said pro forma EPS would have risen 9%. Management expects fiscal 2027 EPS to grow.
Fourth-quarter sales were $265.9 million, up 8%, while fourth-quarter diluted EPS was $0.74 versus $0.78 a year earlier.
Full-year adjusted EBITDA was $179.0 million, up 6%, and operating cash flow was $144.3 million, up 30%.
Total debt was $244.0 million at fiscal year-end, and the leverage ratio rose to 1.37x from 0.86x.
For fiscal 2027, management expects EPS to grow and an income tax rate of 25% to 27%.
Talphera reported a first quarter 2026 net loss of $2.6 million, or $0.04 per share, roughly flat in dollars from a year earlier but improved per share after a larger share count and a $1.2 million warrant liability gain. Operating expenses rose to $3.9 million from $2.9 million, and the company reported no revenue compared with $27 thousand a year earlier, so the operating loss widened. The company said NEPHRO CRRT enrollment has exceeded the 50% milestone and it expects study completion later in 2026.
Q1 2026 net loss was $2.6 million, or $0.04 per share, versus $2.6 million, or $0.10 per share, in Q1 2025
Loss from operations was $3.9 million versus $2.9 million a year earlier; revenue was zero versus $27 thousand
Cash and investments were $21.1 million at March 31, 2026, up from $20.4 million at December 31, 2025
In March 2026 the company closed a $4.1 million third tranche of its March 2025 private placement after reaching the 35-patient enrollment milestone
Acrivon Therapeutics reported a first-quarter 2026 net loss of $19.0 million, or $0.49 per share, compared with $19.7 million, or $0.51 per share, a year earlier. Lower general and administrative expenses offset flat research and development spending, and the company said its cash is expected to fund operations into the third quarter of 2027.
Net loss for the quarter ended March 31, 2026 was $19.0 million, versus $19.7 million a year earlier; net loss per share was $0.49, versus $0.51.
General and administrative expenses fell to $4.7 million from $6.2 million, mainly due to lower employee-related expenses including stock-based compensation.
Research and development expenses were $15.2 million, versus $15.4 million a year earlier.
Cash, cash equivalents and marketable securities were $97.7 million at March 31, 2026, plus $7.3 million in proceeds from subsequent equity financing.
Cisco reported fiscal third quarter 2026 revenue of $15.8 billion, up 12% year over year, with GAAP net income of $3.4 billion, up 35%, and non-GAAP EPS of $1.06, up 10%. The company also announced a restructuring plan with pre-tax charges of up to $1 billion, mostly cash-based, which shareholders should weigh against the growth figures and the fourth-quarter and full-year guidance.
Q3 fiscal 2026 revenue was $15.8 billion, up 12%; GAAP EPS was $0.85, up 37%; non-GAAP EPS was $1.06, up 10%.
Q4 fiscal 2026 guidance: revenue of $16.7 billion to $16.9 billion and non-GAAP EPS of $1.16 to $1.18.
FY 2026 guidance: revenue of $62.8 billion to $63.0 billion and non-GAAP EPS of $4.27 to $4.29.
Restructuring plan: pre-tax charges of up to $1 billion, with about $450 million expected in Q4 fiscal 2026 and the remainder in fiscal 2027.
Journey Medical reported first-quarter 2026 results for the three months ended March 31, 2026. Total revenue rose 21% to $16.0 million and the net loss narrowed to $2.2 million, or $(0.08) per share, from $4.1 million, or $(0.18) per share, a year earlier. Gross margin fell to 61.0% because of a $1.3 million non-cash inventory write-down tied to a 2021 Qbrexza asset acquisition.
Total revenue was $16.0 million, up from $13.1 million in the first quarter of 2025.
Emrosi revenue was $6.3 million, compared with $2.1 million a year earlier.
Gross margin decreased to 61.0% from 63.5%, mainly due to a $1.3 million non-recurring non-cash charge.
Cash and cash equivalents were $27.2 million at March 31, 2026, up from $24.1 million at December 31, 2025.
Aytu BioPharma reported fiscal 2026 third-quarter net revenue of $12.4 million, down from $18.5 million a year earlier, and a net loss of $5.6 million, compared with net income of $4.0 million in the prior-year quarter. The company attributed the revenue decline mainly to lower ADHD Portfolio and Pediatric Portfolio sales as its marketing shifted toward the newly launched EXXUA, which contributed $2.4 million.
Net revenue was $12.4 million versus $18.5 million in Q3 fiscal 2025; ADHD Portfolio fell to $9.1 million from $15.4 million.
EXXUA net revenue was $2.4 million; the product was made commercially available in mid-December 2025 and formally launched in mid-January 2026.
Net loss was $5.6 million, or $0.53 per basic share, versus net income of $4.0 million, or $0.65 per basic share; the result includes a $1.3 million derivative warrant liability loss.
Adjusted EBITDA was $(2.8) million versus $3.9 million a year earlier; cash and cash equivalents were $26.7 million at March 31, 2026.
Doximity reported fiscal fourth-quarter 2026 revenue of $145.4 million, up 5%, but GAAP net income fell to $19.1 million from $62.5 million and adjusted EBITDA declined 6%. The company also gave fiscal 2027 revenue guidance of $664 million to $676 million and named Matthew Sonefeldt as chief financial officer and Steven L. Zatz, M.D. as president, both effective May 13, 2026.
Q4 revenue $145.4 million vs. $138.3 million; net income $19.1 million vs. $62.5 million; diluted EPS $0.10 vs. $0.31
Q4 adjusted EBITDA $65.8 million vs. $69.7 million; full-year fiscal 2026 revenue $644.9 million, up 13%
Fiscal 2027 guidance: revenue $664 million to $676 million; adjusted EBITDA $323 million to $335 million; fiscal Q1 revenue $151 million to $152 million
Matthew Sonefeldt becomes principal financial officer June 8, 2026; Siddharth Sitaram serves as interim PFO through June 7, 2026
Grocery Outlet reported a first-quarter fiscal 2026 net loss of $180.3 million, or $(1.83) per diluted share, compared with a net loss of $23.3 million, or $(0.24), a year earlier. The loss reflects a $158.0 million non-cash goodwill impairment, while net sales rose 3.6% to $1.17 billion, and the company reaffirmed its fiscal 2026 guidance. For shareholders, sales growth was offset by a sharp decline in profit and a much larger per-share loss.
Net sales rose 3.6% to $1.17 billion, but comparable store sales declined 1.0%.
Net loss was $180.3 million, or $(1.83) per diluted share, versus $23.3 million, or $(0.24), a year earlier, including the $158.0 million goodwill impairment.
Adjusted EBITDA was $43.1 million, or 3.7% of net sales, compared with $51.9 million, or 4.6%, last year.
Fiscal 2026 guidance was reaffirmed, including adjusted EBITDA of $220 million to $235 million and diluted adjusted EPS of $0.45 to $0.55.
STAAR Surgical reported first-quarter 2026 results for the period ended April 3, 2026, with net sales of $93.5 million, up 119.6% from a year earlier, and net income of $5.2 million, or $0.10 per diluted share, compared with a net loss of $54.2 million a year earlier. Net sales excluding China rose 6.0% to $46.1 million, and the company reported no outstanding debt as of April 3, 2026.
Net sales of $93.5 million, up 119.6% from $42.6 million in the first quarter of 2025, primarily reflecting China
Gross margin of 73.6% compared with 65.8% a year earlier
Adjusted EBITDA of $24.4 million, or $0.48 per diluted share, compared with a $26.3 million loss a year earlier
Cash and investments available for sale of $163.9 million at April 3, 2026; net cash used in operating activities was $21.7 million
Neonode reported results for the quarter ended March 31, 2026. Revenue from continuing operations rose 19.7% to $0.6 million, driven by new license agreements, while operating expenses rose 8.6% to $2.7 million, mainly from higher professional fees. The loss from continuing operations widened to $1.9 million, or $0.11 per share, from $1.8 million, or $0.11 per share, a year earlier.
Revenue from continuing operations was $0.6 million, up 19.7% from the prior-year quarter.
Loss from continuing operations was $1.9 million, or $0.11 per share, compared with $1.8 million, or $0.11 per share, a year earlier.
Cash used in operations was $2.1 million, compared with $1.4 million a year earlier.
Cash and accounts receivable totaled $23.8 million at March 31, 2026, down from $25.8 million at December 31, 2025.
Lite Strategy reported results for the three and nine months ended March 31, 2026, focused on yield from its Litecoin holdings and share repurchases. The press release does not state revenue, net income or earnings per share, so the filing gives no clear direction on profit. Shareholders get updates on covered call income, buybacks under a $25 million authorization, and a March 2026 SEC statement on Litecoin.
Covered call option program generated $0.7 million in net proceeds since October 2025.
Share repurchases since October 2025 total 1,629,136 shares, under a $25 million authorization.
In March 2026, the SEC issued guidance that LTC exhibits characteristics of a digital commodity, according to the release.
The release does not include revenue, net income or EPS figures.
Bloomia Holdings reported results for the three and nine months ended March 31, 2026, in a press release furnished as Exhibit 99.1 to a Form 8-K. Third-quarter net revenue rose to $14.4 million from $12.4 million, but the company posted a net loss attributable to Bloomia Holdings of $0.8 million, or $0.43 per diluted share, compared with net income of $0.4 million, or $0.25 per share, a year earlier. For the nine months, the loss attributable to the company widened to $5.9 million, or $3.33 per share, and management cited rising raw material costs, tariffs and currency pressure.
Q3 net revenue was $14.4 million vs. $12.4 million a year earlier; gross margin was 19.8% vs. 31.3%.
Q3 net loss attributable to Bloomia Holdings was $0.8 million, or $0.43 per diluted share, vs. net income of $0.4 million, or $0.25 per share.
Nine-month net loss attributable to Bloomia Holdings was $5.9 million, or $3.33 per share, vs. $3.6 million, or $2.04 per share; cash used in operations was $11.1 million.
Rights offering expired April 1, 2026, with gross proceeds of $12.1 million at $4.05 per share, including $7.1 million from conversion of debt.
Spruce Biosciences reported a first-quarter 2026 net loss of $12.3 million, or $(8.94) per share, down from $14.0 million, or $(23.95) per share, a year earlier, as operating expenses fell to $12.0 million from $14.5 million. The company closed a $69.0 million gross underwritten public offering on April 22, 2026, which included 1,150,000 shares, pre-funded warrants and 180,000 option shares, and reported preliminary, unaudited cash of $107.3 million as of April 30, 2026. Shareholders should note that the offering increases the share count, and the company's stated timeline for a BLA submission for TA-ERT is the fourth quarter of 2026.
Net loss of $12.3 million, or $(8.94) per share, for the quarter ended March 31, 2026, versus $14.0 million, or $(23.95) per share, a year earlier.
Total operating expenses of $12.0 million versus $14.5 million; R&D included $5.7 million in one-time product acquisition costs related to SPR202.
Cash and cash equivalents of $54.1 million at March 31, 2026, up from $48.9 million at December 31, 2025.
Closed $69.0 million in aggregate gross offering proceeds on April 22, 2026; preliminary, unaudited cash of $107.3 million as of April 30, 2026.
Protara Therapeutics reported a first-quarter 2026 net loss of $17.8 million, or $0.31 per share, up from $11.9 million, or $0.29 per share, a year earlier. The filing reports no revenue, and the loss widened as research and development and general and administrative expenses rose, but the company said its $177.4 million in cash and marketable securities should fund operations into 2028.
Net loss of $17.8 million, or $0.31 per share, for the quarter ended March 31, 2026, versus $11.9 million, or $0.29 per share, a year earlier
Research and development expenses rose to $13.6 million from $9.1 million, mainly due to ADVANCED-2 trial costs and ADVANCED-3 start-up costs
Cash, cash equivalents and marketable debt securities totaled $177.4 million as of March 31, 2026, expected to support operations into 2028
The company intends to submit a Biologics License Application for TARA-002 in lymphatic malformations in the second half of 2027
Vishay Intertechnology reported first-quarter 2026 results for the fiscal quarter ended April 4, 2026, with revenue of $839.2 million, up from $715.2 million in the year-earlier quarter, and GAAP diluted EPS of $0.05 versus a loss of $0.03 a year earlier. The company guided second-quarter 2026 revenue to $875 million to $905 million with a gross margin of 22.0% plus or minus 50 basis points.
Q1 2026 net revenues were $839.2 million, compared with $715.2 million in the quarter ended March 29, 2025, and $800.9 million in the quarter ended December 31, 2025.
Q1 2026 GAAP diluted EPS was $0.05, compared with a loss of $0.03 a year earlier; gross margin was 21.0%.
Q2 2026 outlook: revenues of $875 million to $905 million and a gross profit margin of 22.0% plus or minus 50 basis points.
Q1 2026 book-to-bill was 1.34; backlog at quarter end was 5.7 months. Free cash was negative $46.9 million, against $54.9 million in the prior quarter.
Upstream Bio reported a first-quarter 2026 net loss of $40.6 million, up from $27.3 million a year earlier, as research and development spending rose to $36.6 million. The company also said it will cap enrollment in its Phase 2 COPD trial and now expects data in the second half of 2027, while cash and short-term investments of $294.6 million are expected to fund operations through 2027.
Net loss was $40.6 million for the quarter ended March 31, 2026, compared with $27.3 million a year earlier.
Research and development expenses rose to $36.6 million from $25.8 million, driven by verekitug clinical and manufacturing costs.
Collaboration revenue was $1.0 million, compared with $0.6 million a year earlier.
Enrollment in the Phase 2 VENTURE COPD trial will be capped, with data now expected in the second half of 2027; Phase 3 starts in severe asthma and CRSwNP are expected in Q1 2027.
Protalix reported first-quarter 2026 total revenue of $33.8 million, up from $10.1 million a year earlier, and net income of $18.3 million, compared with a net loss of $3.6 million in the prior-year quarter. The increase was driven mainly by a $25.0 million milestone from partner Chiesi, and the company reaffirmed its 2026 total revenue guidance of $78.0 million to $83.0 million, which includes that milestone.
Total revenue was $33.8 million for the quarter ended March 31, 2026, versus $10.1 million a year earlier.
Net income was $18.3 million, or $0.23 per share basic and $0.22 diluted, versus a net loss of $3.6 million, or $(0.05) per share, in Q1 2025.
Revenue from selling goods fell to $7.4 million from $10.0 million, mainly due to a timing shift in Pfizer's Elelyso purchases.
The company reaffirmed 2026 total revenue guidance of $78.0 million to $83.0 million and reported cash and short-term deposits of $51.1 million as of March 31, 2026.
Dynatrace reported fourth-quarter and full-year fiscal 2026 results, with quarterly revenue up 19% and ARR up 18%, while GAAP net income fell to $17 million from $39 million a year earlier. The company also issued fiscal 2027 guidance for total revenue of $2,317 million to $2,335 million and non-GAAP earnings per diluted share of $1.93 to $1.95, and it spent $224 million on share repurchases in the quarter.
Q4 total revenue was $532 million, up 19%, and total ARR was $2,054 million, up 18%.
Q4 GAAP net income was $17 million, or $0.06 per diluted share, versus $39 million, or $0.13, a year earlier; GAAP results included an $18.5 million impairment of long-lived assets.
Q4 non-GAAP net income per diluted share was $0.41, up from $0.33.
Fiscal 2027 guidance: total revenue of $2,317 million to $2,335 million and non-GAAP net income per diluted share of $1.93 to $1.95.
National Vision reported first quarter 2026 results for the period ended April 4, 2026, with net revenue up 6.6% to $543.9 million and net income of $31.2 million, compared with $14.2 million a year earlier. Diluted EPS rose to $0.38 from $0.18, and the company reiterated its fiscal 2026 outlook, including Adjusted Diluted EPS of $0.85 to $1.09.
Net revenue rose 6.6% to $543.9 million; comparable store sales grew 4.4%.
Diluted EPS was $0.38 versus $0.18; Adjusted Diluted EPS was $0.45 versus $0.34.
Fiscal 2026 outlook reiterated: net revenue of $2.033 billion to $2.091 billion and Adjusted Diluted EPS of $0.85 to $1.09.
Expanded relationship with AAFES, effective April 1, 2026, adds 20 Military stores and makes National Vision the sole optical retail partner on U.S. AAFES bases.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.